Home Newsfeeds DA Davidson Maintains Neutral on First Busey, Lowers Price Target to $25

DA Davidson Maintains Neutral on First Busey, Lowers Price Target to $25

DA Davidson analyst Jeff Rulis maintains First Busey (NASDAQ:BUSE) with a Neutral and lowers the price target from $27 to $25.

byBenzinga Newsdesk

January 26, 2023

1 minute read

DA Davidson analyst Jeff Rulis maintains First Busey (NASDAQ:BUSE) with a Neutral and lowers the price target from $27 to $25.

Natera Announces New Publication From I-SPY2 Trial Reinforcing Clinical Utility Of Signatera For Breast Cancer Patients In The Neoadjuvant Setting

By Happy Mohamed

May 8, 8:04 AM

Study with 283 patients, >1,000 plasma samples, and longest follow-up exceeding 5 years demonstrates how ctDNA monitoring can help inform treatment decisions in HR+/HER2- and TNBC patients Natera,

NTRA

SAB Biotherapeutics To Present Novel Human IgG Platform With Data And Breakthrough Therapy And Fast-Track Designations For Influenza Treatment At BIO 2023 International Convention

By Happy Mohamed

May 30, 8:37 AM

SAB Biotherapeutics (NASDAQ:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG)

SABS

Chimera Investment Corporation Announces Q2 2023 Common Stock Dividend Of $0.18 And Increase In Share Repurchase Program From $177M To $250M

By Benzinga Newsdesk

June 14, 4:34 PM

Chimera Investment Corporation (NYSE:CIM) (the "Company" or "Chimera") announced today that its Board of Directors declared the second quarter common stock dividend. The Company also announced an increase in the amount

CIM

Barclays Maintains Underweight on Illinois Tool Works, Lowers Price Target to $172

By Benzinga Newsdesk

October 3, 8:13 AM

Barclays analyst Julian Mitchell maintains Illinois Tool Works (NYSE:ITW) with a Underweight and lowers the price target from $179 to $172.

ITW

DA Davidson Maintains Neutral on First Busey, Lowers Price Target to $25

Related Posts

Natera Announces New Publication From I-SPY2 Trial Reinforcing Clinical Utility Of Signatera For Breast Cancer Patients In The Neoadjuvant Setting

SAB Biotherapeutics To Present Novel Human IgG Platform With Data And Breakthrough Therapy And Fast-Track Designations For Influenza Treatment At BIO 2023 International Convention

Chimera Investment Corporation Announces Q2 2023 Common Stock Dividend Of $0.18 And Increase In Share Repurchase Program From $177M To $250M

Barclays Maintains Underweight on Illinois Tool Works, Lowers Price Target to $172